Started conducting preclinical research on cell drugs in 2013;
Participated as a joint unit in the National Ministry of Science and Technology's major new drug development project "Preclinical and Clinical Research of Endometrial Regenerative Cell Drugs";
Undertake the construction of the "Common Key Technology Platform for Stem Cell Product Evaluation" for the Tianjin New Drug Creation Technology Major Project;
Establish a professional cellular drug evaluation technology platform, covering comprehensive evaluations of pharmacology, pharmacokinetics, and toxicology;
Provide research and development services that support clinical research filing and clinical trial registration;
Provided product research and development services to more than 50 domestic cell drug research enterprises, helping to obtain implied licenses for 7 clinical trials;
Director of the China Stem Cell Industry Alliance;